Research has revealed interaction between NLRP3 and TREM2 signaling, indicating that modulating the NLRP3 inflammasome to maintain TREM2 function could offer therapeutic potential for C9orf72-ALS/FTD [139]. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.